Levetiracetam: A possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 113-115

  Duong, Tu Anh ^a,b   Haddad, Cynthia ^a,c   Valeyrie Allanore, Laurence ^a,b,c,d   Sbidian, Emilie ^a,d,e   Chosidow, Olivier ^a,b,d,f   Wolkenstein, Pierre ^a,b,d,e  

^a HENRI MONDOR HOSPITAL   (France)

^b Centre de Reference des Dermatoses Bulleuses Toxiques   (France)

^c RegiSCAR Group   (France)

^d EA no EA439   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBAZAM; ETIRACETAM; FOLIC ACID; IRON; LOXAPINE; METRONIDAZOLE; SULFADIAZINE; VORICONAZOLE;

ADULT; ALGORITHM OF DRUG CAUSALITY FOR EPIDERMAL NECROLYSIS; ASPERGILLUS NIGER; CASE REPORT; EXTERNAL OTITIS; FEMALE; FRENCH PHARMACOVIGILANCE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INTRACRANIAL TUBERCULOMA; LETTER; NARANJO SCORE; PRIORITY JOURNAL; SCORING SYSTEM; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRAUMATIC BRAIN INJURY;

ADULT; ANTICONVULSANTS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; PIRACETAM; STEVENS-JOHNSON SYNDROME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84873437210     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.266     Document Type: Letter

References (5)

1. US Food and Drug Administration. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between July-September 2010. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm237585.htm. Accessed April 17, 2012.
2. Lens S, Crespo G, Carrión JA, Miquel R, Navasa M. Severe acute hepatitis in the DRESS syndrome: Report of two cases. Ann Hepatol. 2010;9(2):198-201.
3. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-68.
4. Benahmed S, Picot MC, Hillaire-Buys D, Blayac JP, Dujols P, Demoly P. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol. 2005;61(7):537-541. (Pubitemid 41218825)
5. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44. (Pubitemid 350249390)